A blockage of IL-4Rα or IL-13, thus inhibiting IL-4 and/or IL-13 activity in asthma, has been shown in preventing asthma exacerbations in the context of withdrawal of LABA and ICS, increases in FEV1 and reductions in the usage of short-acting beta-2 agonists in patients with moderate to severe asthma [31,32]. Here, IL4R is linked to asthma.